Immunotherapy has emerged as a groundbreaking treatment option for lung cancer, offering new hope to patients who previously had limited options. Unlike traditional therapies such as chemotherapy and radiation, immunotherapy works by empowering the body's immune system to recognize and attack cancer cells.

What Is Immunotherapy?

Immunotherapy involves the use of medications called immune checkpoint inhibitors, which help to remove the "brakes" on immune cells. This allows the immune system to better identify and destroy cancer cells. It is particularly effective in non-small cell lung cancer (NSCLC), the most common type of lung cancer.

How Does Immunotherapy Work in Lung Cancer?

In lung cancer, tumors often produce proteins that inhibit immune responses. Immunotherapy drugs target these proteins, such as PD-1 and PD-L1, restoring immune activity. This process can lead to durable responses and prolonged survival in some patients.

Commonly Used Immunotherapy Drugs

  • Nivolumab (Opdivo)
  • Pembrolizumab (Keytruda)
  • Atezolizumab (Tecentriq)

Benefits and Limitations

Immunotherapy can lead to significant improvements in quality of life and survival for some patients. However, it does not work for everyone, and some may experience side effects such as fatigue, skin reactions, or immune-related adverse events. It is important for doctors to evaluate each patient's specific situation.

Future Directions in Lung Cancer Immunotherapy

Research continues to explore combination therapies, new targets, and biomarkers to predict response. Advances in personalized medicine aim to optimize immunotherapy benefits for more lung cancer patients in the future.